Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 20
- Registration Number
- NCT00000728
- Locations
- 🇺🇸
Stanford Univ School of Medicine, Stanford, California, United States
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 819
- Registration Number
- NCT00000637
- Locations
- 🇺🇸
Children's Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States
🇺🇸UCLA Med Ctr / Pediatric, Los Angeles, California, United States
A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 64
- Registration Number
- NCT00000743
- Locations
- 🇺🇸
Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU, New Orleans, Louisiana, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 400
- Registration Number
- NCT00000750
- Locations
- 🇺🇸
UCLA Med Ctr / Pediatric, Los Angeles, California, United States
🇺🇸Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States
A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 72
- Registration Number
- NCT00001010
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 16
- Registration Number
- NCT00000670
- Locations
- 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002411
- Locations
- 🇺🇸
Northwestern Univ / Div of Infect Diseases, Chicago, Illinois, United States
🇺🇸Rush Presbyterian / ST Lukes Med Ctr, Chicago, Illinois, United States
🇺🇸Univ of Texas / Med Branch at Galveston, Galveston, Texas, United States
A Study of Azidothymidine in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 75
- Registration Number
- NCT00000982
- Locations
- 🇺🇸
Walter Reed / USUHS / Pediatrics, Bethesda, Maryland, United States
🇺🇸Children's Hosp at Albany Med Ctr, Albany, New York, United States
🇺🇸Univ of Florida Med Ctr, Jacksonville, Florida, United States
A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 70
- Registration Number
- NCT00000716
- Locations
- 🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-14
- Target Recruit Count
- 80
- Registration Number
- NCT00000659
- Locations
- 🇺🇸
Tulane Univ School of Medicine, New Orleans, Louisiana, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.